Drugs / Serdexmethylphenidate/dexmethylphenidate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06000501 | Nov 2023 → Jul 2024 | attention deficit-hyperactivity disorder | NYU Langone Health | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Serdexmethylphenidate/dexmethylphenidate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06000501 ↗ |
| Known as | Azstarys | “An Open-Label Treatment, Investigator-Initiated Study, on the Duration and Efficacy of Azstarys (Serdexmethylphenidate and Dexmethylphenidate) on Adult ADHD Symptoms and...” NCT06000501 ↗ |
| Route | Oral | “Azstarys capsules for once-daily oral use for three weeks.” NCT06000501 ↗ |